Research conducted by 21st Century Oncology, in collaboration with UCLA, Stanford, and other esteemed cancer research centers, was selected for a “Best of ASTRO” award, which recognizes the top 10 research submissions.
| FORT MYERS, Fla. /PRNewswire/ -- Research conducted by 21st Century Oncology, in collaboration with UCLA, Stanford, and other esteemed cancer research centers, was selected for a “Best of ASTRO” award, which recognizes the top 10 research submissions. The abstract titled, “Long-Term Outcomes of Stereotactic Body Radiation Therapy for Low – and Intermediate-Risk Prostate Adenocarcinoma: A Multi-Institutional Consortium Study,” was presented by Dr. Amar U. Kishan, a resident at UCLA, at the 2018 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Antonio, TX on Oct. 22. Prostate SBRT (Stereotactic Body Radiation Therapy) is a recent and highly advanced method of radiation therapy that delivers a curative radiation dose to the prostate over a short-term treatment period of five visits. 21st Century Oncology was among the very first treatment centers internationally to treat patients using this technology in 2002. Since then, 21st Century Oncology has enrolled hundreds of patients into this research study and has published results that demonstrate high rates of cure with very few or serious side effects. “I am very proud of our research efforts at 21st Century Oncology,” said Dr. Constantine Mantz, M.D., Chief Policy Officer, 21st Century Oncology “We can now offer this treatment as a standard of care for selected patients with early-stage prostate cancer.” Constantine Mantz, M.D. was the contributing 21st Century Oncology physician in conjunction with Amar U. Kishan,M.D.; Alan J. Katz, M.D.; Fang-I Chu, Ph.D.; Limor Appelbaum, M.D.; and Andrew Loblaw, M.D., F.R.C.P.C, M.Sc. About 21st Century Oncology Media Contact: Samantha Scott, APR
SOURCE 21st Century Oncology |
View original content:
